Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Clinical case of Aicardi–Goutières syndrome type 6
V. A. Akimova,
E. E. Repa,
V. A. Marymova,
O. S. Selezneva,
E. V. Dudnikova,
E. A. Besedina,
A. S. Badyan,
A. V. Dyuzheva,
E. V. Nesterova https://doi.org/10.21508/1027-4065-2025-70-2-77-82
Abstract
Primary immunodeficiencies are a group of heterogeneous diseases caused by genetic deficiency of one or another component of the immune system. Due to the lack of focus of doctors on primary immunodeficiencies in patients and the phenotypic heterogeneity of nosologies included in this group, a high percentage of undiagnosed cases are determined. A genetic cause is detected only in about 30% of patients, and most of them do not have an obvious family history. Aicardi–Goutieres syndrome is a rare monogenic autoimmune disease that primarily affects the brain in children and is caused by mutations in one of the 9 genes responsible for nucleic acid metabolism and is accompanied by increased expression of interferon-stimulated genes (interferonopathy type I). In particular, in Aicardi–Goutieres syndrome type 6 (AGS6, OMIM 615010), a mutation in the ADAR gene (locus 1q21.3) leads to the recognition of unedited double-stranded RNA with the initiation of an interferon synthesis reaction. The article presents a clinical case of AGS6 syndrome, OMIM 615010, diagnosed posthumously in a 12-year-old boy.
About the Authors
V. A. Akimova
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
E. E. Repa
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
V. A. Marymova
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
O. S. Selezneva
Regional Children’s Clinical Hospital
Russian Federation
Russian Federation
Rostov-on-Don
E. V. Dudnikova
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
E. A. Besedina
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
A. S. Badyan
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
A. V. Dyuzheva
Regional Children’s Clinical Hospital
Russian Federation
Russian Federation
Rostov-on-Don
E. V. Nesterova
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
References
1. Thaventhiran J.E.D., Lango Allen H., Burren O.S., Rae W., Greene D., Staples E., et al. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature 2020; 583(7814): 90–95. DOI: 10.1038/s41586–020–2265–1
2. Tuzankina I.A., Deryabina S.S., Bolkov M.A., Bass E.A., Vlasova E.V., Krokhaleva Ya.M., Shershnev V.N. Primary immunodeficiencies in children at an early age. Moscow, 2018; 176 p. (in Russ.) https://pid-spb.ru/Tuzankina_EarlyPID.pdf / Ссылка активна на 4.03.2025
3. Liu A., Ying S. Aicardi-Goutières syndrome: A monogenic type I interferonopathy. Scand J Immunol 2023; 98(4): e13314. DOI: 10.1111/sji.13314
4. Crow Y.J. Aicardi–Goutières syndrome. Handb Clin Neurol 2013; 113: 1629–1635. DOI: 10.1016/B978–0–444–59565–2.00031–9
5. Munoz J., Marque M., Dandurand M., Meunier L., Crow Y-J., Bessis D., et al. Type I interferonopathies [Article in French] Ann Dermatol Venereol 2015; 142(11): 653–663. DOI: 10.1016/j.annder.2015.06.018
6. Nakahama T., Kawahara Y. The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways. Int Immunol 2023; 35: 123–133. DOI: 10.1093/intimm/dxac056
7. Song B., Shiromoto Y., Minakuchi M., Nishikura K. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdiscip Rev RNA 2022; 13: e1665. DOI: 10.1002/wrna.1665
8. Козлова А.Л., Романенко Е.С., Бурлаков В.И., Дерипапа Е.В., Хомякова С.П., Ремизов А.Н. и др. Клинический случай интерферонопатии I типа: синдром Айкарди– Гутьерес. Педиатрия 2019; 98(3): 257–265.
9. Livingston J.H., Lin J.-P., Dale R.C., Gill D., Brogan P., Munnich A., et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet 2014; 51: 76–82.
10. Crow Y.J., Zaki M.S., Abdel-Hamid M.S., Abdel-Salam G., Boespflug-Tanguy O., Cordeiro N., et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics 2014; 45: 386–391. DOI: 10.1055/s-0034–1389161
11. Adang L., Gavazzi F., De Simone M., Fazzi E., Galli J., Koh J., et al. Developmental Outcomes of Aicardi Goutières Syndrome. J Child Neurol 2020; 35(1): 7–16. DOI: 10.1177/0883073819870944
12. Crow Y.J., Shetty J., Livingston J.H. Treatments in Aicardi– Goutières syndrome. Dev Med Child Neurol 2020; 62(1): 42–47. DOI: 10.1111/dmcn.14268
Review
For citations:
Akimova V.A., Repa E.E., Marymova V.A., Selezneva O.S., Dudnikova E.V., Besedina E.A., Badyan A.S., Dyuzheva A.V., Nesterova E.V. Clinical case of Aicardi–Goutières syndrome type 6. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2025;70(2):77-82. (In Russ.) https://doi.org/10.21508/1027-4065-2025-70-2-77-82
Views:
242
Email this article 